Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Nature - 17 Sept 2009

Ge Dongliang, Fellay Jacques, Thompson Alexander J, Simon Jason S, Shianna Kevin V, Urban Thomas J, Heinzen Erin L, Qiu Ping, Bertelsen Arthur H, Muir Andrew J, Sulkowski Mark, McHutchison John G, Goldstein David B

Abstract excerpt

Chronic infection with hepatitis C virus (HCV) affects 170 million people worldwide and is the leading cause of cirrhosis in North America. Although the recommended treatment for chronic infection involves a 48-week course of peginterferon-alpha-2b (PegIFN-alpha-2b) or -alpha-2a (PegIFN-alpha-2a)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interferon alpha-2
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hispanic or Latino

Share to Asia, Eastern

Share to Chromosomes, Human, Pair 19

Share to Interferons

Share to Interleukins

Share to Polyethylene Glycols

Source

Identifiers

PMID: 19684573
DOI: 10.1038/nature08309

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19684573-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.PMID 19684573Read ↗

IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection.Semantic proximity Read ↗

The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.Semantic proximity Read ↗

IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.Semantic proximity Read ↗

The role of genetic markers in hepatitis C virus therapy: a major step for individualized care.Semantic proximity Read ↗

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.Semantic proximity Read ↗

IL28B single nucleotide polymorphisms in the treatment of hepatitis C.Semantic proximity Read ↗

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.Semantic proximity Read ↗

Role of IL28B for chronic hepatitis C treatment toward personalized medicine.Semantic proximity Read ↗

IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations.Semantic proximity Read ↗

Host genomics and HCV treatment response.Semantic proximity Read ↗

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.Semantic proximity Read ↗

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.